News

As part of a collaboration between both the parties, which was signed in 2010, Xenon will now be responsible for all future development and commercialization of XEN701. XEN701

Following to completion of review of the Trokendi XR new drug application as revised in December 2012, the regulator approved the product for use as recommended in the

The Protein Purification Facility will leverage the cGMP compatible stable, non-lytic protein expression platform for expression of complex and challenging proteins, including Fab fragments and other proteins. ExpreS2ion

The Irys benchtop instrument is fully automated and uses the IrysChip to uncoil and confine long DNA molecules in Nanochannel Arrays, where molecules are then uniformly distributed in

With an orphan drug status for the treatment of acute myeloid leukemia (AML), the novel targeted therapy is directed to the interleukin-3 receptor (IL-3R) present on tumor bulk

In exchange, BioLineRx will receive an upfront license fee, along with future development, regulatory and commercialisation milestones together worth approximately $30m in addition to projected sales-based royalties. CTTQ

As the first and only four-strain influenza vaccine option for patients as young as six months of age, Fluzone Quadrivalent vaccine is the newest addition to the Fluzone

iMed will leverage IT solutions to share and manage complex data with clinical trial investigators and other external partners on a common portal. AZ NS iMed vice president

Expected to be set up within a year, the new pharmaceutical technology centre will focus on drug discovery, process development and commercialization, drug characterization, drug delivery and diagnostics.